GlassScriptPhysician profile
Herbert Duvivier
NPI 1710982731
$108,806.37
in general payments reported to CMS, 2019-2025
66 companies · $3,549 in 2025
The $3,549 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $8,398 · 2021: $17K · 2022: $17K · 2023: $8,663 · 2024: $617 · 2025: $3,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,105 · Food and Beverage: $4,210 · Travel and Lodging: $568 · Consulting Fee: $550 · Education: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,105.00 |
| Food and Beverage | $4,210.34 |
| Travel and Lodging | $567.81 |
| Consulting Fee | $550.00 |
| Education | $395.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $42,389.03 | 2019-2025 | Tagrisso, Lynparza, Enhertu |
| Merck Sharp & Dohme LLC | $23,434.74 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Regeneron Healthcare Solutions, INC. | $19,595.14 | 2021-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $6,302.23 | 2019-2023 | |
| Rigel Pharmaceuticals, INC. | $3,872.95 | 2019 | |
| Daiichi Sankyo INC. | $3,328.30 | 2020-2025 | Enhertu |
| Genzyme Corporation | $1,718.90 | 2019-2025 | |
| Janssen Biotech, INC. | $1,043.88 | 2019-2025 | Rybrevant, Erleada, Tecvayli |
| Novartis Pharmaceuticals Corporation | $972.71 | 2019-2025 | |
| Pfizer INC. | $621.00 | 2019-2025 | |
| Beigene USA, INC. | $568.92 | 2021-2023 | Brukinsa |
| Amgen INC. | $428.92 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $425.62 | 2019-2025 | Opdivo, Reblozyl |
| Glaxosmithkline, LLC. | $364.40 | 2022-2025 | Zejula, Ojjaara |
| Astellas Pharma US INC | $289.33 | 2019-2024 | Padcev |
Show all 64 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herbert Duvivier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.